T Cell Signature in Biliary Atresia

Case ID:
Disclosure Date:
Unmet Need
Biliary atresia is a pediatric disease that is difficult to diagnose. Surgical intervention is sometimes capable of correcting the disorder, but undiagnosed and subsequently untreated infants will likely die of liver failure within the first three months after birth. While infants suffering from the disorder are born and jaundiced, it is not immediately clear whether this is benign self-limited jaundice) which is of no consequence to the child) or if this is the life-threatening disease, biliary atresia. This invention may provide a method for more accurately and quickly identifying infants at birth, allowing for more rapid surgical intervention and decreased rates of infant mortality.
Technology Overview
Johns Hopkins researchers have identified a molecular sequence that is detectable in a patient sample, such as blood or a liver biopsy. Specifically identified is a unique T-cell clone detected in 50% of examined samples from patients diagnosed with biliary atresia. These data may be useful in the creation of a molecular test for the diagnosis of biliary atresia.  The patient sample may be sent for molecular DNA sequencing, and if the unique sequence is present the patient may be more rapidly identified as a candidate for intervention.
Stage of Development
The inventors have conducted an initial study that has identified the unique sequence in approximately 50% of the tested samples. An expanded study to further validate the presence and frequency of this sequence in a wider array of samples will be conducted.
Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
T cell signature in biliary atresia PRO: Provisional United States 62/525,683 6/27/2017     Pending
For Information, Contact:
Nakisha Holder
Save This Technology:
2017 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum